{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:51:30Z","timestamp":1782251490511,"version":"3.54.5"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["No. 2023J011690"],"award-info":[{"award-number":["No. 2023J011690"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical and health guidance project of Xiamen science and technology bureau","award":["3502Z20244ZD1115"],"award-info":[{"award-number":["3502Z20244ZD1115"]}]},{"name":"Fujian Province Department of Science and Technology","award":["2022D014"],"award-info":[{"award-number":["2022D014"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To investigate the impact of latent tuberculosis infection (LTBI) on the prognosis of non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 immunotherapy and to assess the correlation between dynamic alterations in T-SPOT.TB results and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed clinical data from 127 patients with NSCLC who received anti-PD-1 therapy and underwent T-SPOT.TB testing at our institution between January 2020 and March 2024. Baseline imbalances between groups were addressed using inverse probability of treatment weighting (IPTW). Restricted cubic spline (RCS) modeling, Cox regression and other analyses were conducted both before and after IPTW.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the entire cohort, 50 patients were in the LTBI group and 77 in the Normal group. No significant differences were observed in mPFS or mOS between the two groups. RCS analysis revealed a nonlinear (U-shaped) relationship between pre-TSPOT values and OS. Patients with a T-SPOT positive (but value\u2009\u2a7d18) exhibited longer OS compared with the other two groups (HR\u2009=\u20090.13, 95% CI [0.03 ~ 0.54],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.005; after IPTW HR\u2009=\u20090.21, 95% CI [0.05-0.90],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.035). Among 63 patients monitored for dynamic TSPOT changes, 35 (55.56%) remained persistently negative, 15 (23.81%) remained persistently positive, 2 (3.17%) converted from negative to positive, and 11 (17.46%) converted from positive to negative. No significant differences in ORR, PFS, or OS across these groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although no statistically significant differences in treatment efficacy and prognosis were observed between the LTBI and Normal groups, this finding should not be interpreted as therapeutic equivalence, particularly given the limited sample size. Pre-treatment T-SPOT values showed a nonlinear (U-shaped) relationship with patient prognosis (OS). Lower pre-treatment T-SPOT value were associated with longer OS. The dynamic changes in T-SPOT during treatment were not significantly associated with outcomes. Four patients developed active tuberculosis during immunotherapy, with heterogeneous T-SPOT patterns, underscoring the need for TB monitoring in ICI-treated patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795549251394955","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T03:04:58Z","timestamp":1764385498000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Latent Tuberculosis Infection and T-SPOT.TB Dynamics Alterations on Prognosis in Advanced NSCLC Treated With ICIs\u2014\u2014IPTW-Based Retrospective Study"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4685-2378","authenticated-orcid":false,"given":"Yijiao","family":"Xu","sequence":"first","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Liu","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-4961","authenticated-orcid":false,"given":"Yijun","family":"Song","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwen","family":"Yang","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congyi","family":"Xie","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaWei","family":"Yang","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9487-2115","authenticated-orcid":false,"given":"Zhisheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-3723","authenticated-orcid":false,"given":"Hongni","family":"Jiang","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China"},{"name":"Xiamen Clinical Research Center for Cancer Therapy, Xiamen, China"},{"name":"Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-IO-S1-s02"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-IO-S1-s05"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823618"},{"key":"e_1_3_3_7_2","first-page":"13","article-title":"Research progress in immune checkpoint inhibitors for lung cancer in China","author":"Gan J","year":"2021","unstructured":"Gan J, Huang Y, Fang W, Zhang L. Research progress in immune checkpoint inhibitors for lung cancer in China. Ther Adv Med Oncol. 2021;13.","journal-title":"Ther Adv Med Oncol"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.016"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13978"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30276-0"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14251"},{"key":"e_1_3_3_12_2","first-page":"21","article-title":"Cellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion","author":"Verdon DJ","year":"2020","unstructured":"Verdon DJ, Mulazzani M, Jenkins MR. Cellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion. Int J Mol Sci. 2020;21.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_13_2","first-page":"60","article-title":"The paradox of immune checkpoint inhibition re-activating tuberculosis","author":"Ahmed M","year":"2022","unstructured":"Ahmed M, Tezera LB, Elkington PT, Leslie AJ. The paradox of immune checkpoint inhibition re-activating tuberculosis. Eur Respir J. 2022;60.","journal-title":"Eur Respir J"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400656"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/15257770.2024.2308522"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14721"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.12.018"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1013751"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1405427"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0261-5614(03)00098-0"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02585-w"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.4103\/sja.SJA_543_18"},{"key":"e_1_3_3_25_2","first-page":"50","article-title":"Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis","author":"Dobler CC","year":"2017","unstructured":"Dobler CC, Cheung K, Nguyen J, Martin A. Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J. 2017;50.","journal-title":"Eur Respir J"},{"key":"e_1_3_3_26_2","first-page":"20","article-title":"The bidirectional relationship between pulmonary tuberculosis and lung cancer","author":"Preda M","year":"2023","unstructured":"Preda M, Tanase BC, Zob DL, et al The bidirectional relationship between pulmonary tuberculosis and lung cancer. Int J Environ Res Public Health. 2023;20.","journal-title":"Int J Environ Res Public Health"},{"key":"e_1_3_3_27_2","first-page":"6","article-title":"PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques","author":"Kauffman KD","year":"2021","unstructured":"Kauffman KD, Sakai S, Lora NE, et al PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques. Sci Immunol. 2021;6.","journal-title":"Sci Immunol"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005667"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.727220"},{"key":"e_1_3_3_30_2","first-page":"9","article-title":"Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha","author":"Tezera LB","year":"2020","unstructured":"Tezera LB, Bielecka MK, Ogongo P, et al Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha. eLife. 2020;9.","journal-title":"eLife"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.02.015"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02194-z"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2358551"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13740"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00114810"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35948-9"},{"key":"e_1_3_3_38_2","first-page":"11","article-title":"Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity","author":"Zheng M.","year":"2023","unstructured":"Zheng M. Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity. J Immunother Cancer. 2023;11.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.69854\/jcq.2024.0016"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro732"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3211"},{"key":"e_1_3_3_42_2","first-page":"51","article-title":"Handbook of ELISPOT: methods and protocols","volume":"2768","author":"Kalyuzhny AE.","year":"2024","unstructured":"Kalyuzhny AE. Handbook of ELISPOT: methods and protocols. Meth Mol Biol. 2024;2768:51-58.","journal-title":"Meth Mol Biol"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03198-1"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1046755"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13832"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549251394955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795549251394955","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795549251394955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:40:30Z","timestamp":1777693230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795549251394955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":44,"alternative-id":["10.1177\/11795549251394955"],"URL":"https:\/\/doi.org\/10.1177\/11795549251394955","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"11795549251394955"}}